Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Rapid Impact Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Metabolism Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Spotlight on Genomic Analysis of Rare and Understudied Cancers
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Research
Molecular Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Rapid Impact Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Metabolism Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Spotlight on Genomic Analysis of Rare and Understudied Cancers
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Cell Fate Decisions

Ovarian Tumor Cell Expression of Claudin-4 Reduces Apoptotic Response to Paclitaxel

Christopher Breed, Douglas A. Hicks, Patricia G. Webb, Carly E. Galimanis, Benjamin G. Bitler, Kian Behbakht and Heidi K. Baumgartner
Christopher Breed
1Department of Obstetrics and Gynecology, Division of Reproductive Sciences, Anschutz Medical Campus, University of Colorado Denver, Aurora, Colorado.
2Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Anschutz Medical Campus, University of Colorado Denver, Aurora, Colorado.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Douglas A. Hicks
1Department of Obstetrics and Gynecology, Division of Reproductive Sciences, Anschutz Medical Campus, University of Colorado Denver, Aurora, Colorado.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patricia G. Webb
1Department of Obstetrics and Gynecology, Division of Reproductive Sciences, Anschutz Medical Campus, University of Colorado Denver, Aurora, Colorado.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carly E. Galimanis
1Department of Obstetrics and Gynecology, Division of Reproductive Sciences, Anschutz Medical Campus, University of Colorado Denver, Aurora, Colorado.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benjamin G. Bitler
1Department of Obstetrics and Gynecology, Division of Reproductive Sciences, Anschutz Medical Campus, University of Colorado Denver, Aurora, Colorado.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kian Behbakht
1Department of Obstetrics and Gynecology, Division of Reproductive Sciences, Anschutz Medical Campus, University of Colorado Denver, Aurora, Colorado.
2Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Anschutz Medical Campus, University of Colorado Denver, Aurora, Colorado.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heidi K. Baumgartner
1Department of Obstetrics and Gynecology, Division of Reproductive Sciences, Anschutz Medical Campus, University of Colorado Denver, Aurora, Colorado.
2Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Anschutz Medical Campus, University of Colorado Denver, Aurora, Colorado.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Heidi.Wilson@ucdenver.edu
DOI: 10.1158/1541-7786.MCR-18-0451 Published March 2019
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Claudin-4 expression in HGSOC cells. A, CLDN4 gene expression levels in laser capture microdissected specimens of human high-grade serous ovarian tumors compared with isolated normal human ovarian surface epithelial cells (36). Western blot analysis of claudin-4 protein levels in human patient samples of normal fallopian tube and ovarian cancer (B) as well as high-grade serous ovarian tumor cell lines (C), using GAPDH as a loading control. Mean ± SEM, n = 10 HOSE, n = 10–53 HGSOC tumor specimens, n = 7 other EOC subtypes (*, P < 0.05; ***, P < 0.0001).

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Disruption of claudin-4 activity with CMP enhances paclitaxel response. A, Representative images of nuclei (DAPI staining) and activated caspase-3 (fluorescent antibody directed to cleaved caspase-3) from OVCAR3 cells. Quantification of caspase-3 activation in OVCAR3 (B) and OVCAR8 (C) cells treated for 24 hours with vehicle control (Veh cont), 400 μmol/L inactive control peptide (ContP), 400 μmol/L CMP, 10 μmol/L Cisplatin (Cis), CMP + Cisplatin, 10 nmol/L paclitaxel (taxol), or CMP + paclitaxel. Percent of cell population positive for caspase-3 activation was calculated using SlideBook software (3i). Mean ± SEM; n = 3; NS, not significant; ***, P < 0.001 versus control/drug only.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Loss of claudin-4 expression enhances paclitaxel response. A, Western blot analysis of claudin-4 protein in OVCAR3 cells treated with control empty vector shRNA (shCTRL) or claudin-4–targeted shRNA (shCLDN4_1, shCLDN4_2, shCLDN4_3). GAPDH was used as a loading control. B, Immunofluorescence analysis of cells treated with 400 μmol/L inactive control peptide (ContP), 400 μmol/L CMP, 10 nmol/L paclitaxel (taxol), or CMP + paclitaxel for 24 hours. Cells were treated with fluorescent antibody directed to cleaved caspase-3 and DAPI (nuclei) and percent of cell population positive for caspase-3 was calculated using SlideBook software (3i). Mean ± SEM, n = 3 per treatment group; NS, not significant; *, P < 0.05, ***, P < 0.001 versus control/paclitaxel only.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Overexpression of claudin-4 reduces paclitaxel response. A, Western blot analysis of claudin-4 protein in OVCAR8 cells transduced with GFP only or claudin-4-GFP. GAPDH was used as a loading control. B, Immunofluorescence analysis of fixed OVCAR8 cells that were treated with 400 μmol/L inactive control peptide (ContP), 400 μmol/L CMP, 10 nmol/L paclitaxel (taxol), or CMP + paclitaxel for 24 hours. Cells were treated with fluorescent antibody directed to cleaved caspase-3 and DAPI (nuclei) and percent of cell population positive for caspase-3 was calculated using SlideBook software (3i). Mean ± SEM; n = 3 per treatment group; NS, not significant; **, P < 0.01; ***, P < 0.001 versus control/paclitaxel only.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Loss of claudin-4 leads to delayed mitotic progression. A, Representative images of DAPI (DNA) staining in fixed monolayers of control knockdown (shCTRL) and claudin-4 knockdown (shCLDN4_2) OVCAR3 cells. Yellow circles highlight mitotic figures. B, Visual counting of mitotic figures from DAPI images. C, Colorimetric measurement of phosphorylated H2B (mitotic marker) to quantify population of mitotic cells in shCTRL (white bars) and shCLDN4_2 (black bars) OVCAR3 cells. D, Proliferation rates of shCTRL (circles/solid line) and shCLDN4_2 (triangles/dotted line) OVCAR3 cells. E, Representative histograms of propidium iodide staining 6 hours after release from serum starvation synchronization in shCTRL and shCLDN4_2 cells. F, Quantification of the percent of the total cell population in the G2–M phase of the cell cycle using FlowJo software. Mean ± SEM; n = 3 (*, P < 0.05; ***, P < 0.001 versus control/paclitaxel only).

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    Claudin-4 interacts with tubulin. A, Proximity ligation assay using antibodies directed at claudin-4 and α-tubulin or β-tubulin. Red fluorescence indicates protein–protein interaction. Yellow outlined boxes are higher magnification of cell from image. Arrows point to sites of protein-protein interaction. B, IP of claudin-4 (cld-4 IP) and IgG (mouse IgG IP) from OVCAR3 lysates blotted for presence of α-tubulin and claudin-4. C, Immunofluorescence of claudin-4 (green) and β-tubulin (red), with DAPI (blue), in mitotic OVCAR3 cell. Yellow color indicates colocalization of claudin-4 and β-tubulin. D, Immunofluorescence of microtubules (β-tubulin; white/red) and nuclei (DAPI/blue) in cells expressing (shCTRL) and not expressing (shCLDN4_2) claudin-4.

  • Figure 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 7.

    Claudin-4 alters tubulin polymerization. A, Representative Western blot analysis of polymerized (P, pellet fraction) and nonpolymerized (S, supernatant fraction) tubulin levels in OVCAR3 cells expressing claudin-4 (shCTRL) and cells with silenced claudin-4 expression (shCLDN4_2). B, Quantification of the percent of the total tubulin that is polymerized. Mean ± SEM; n = 4 (**, P < 0.01).

Additional Files

  • Figures
  • Supplementary Data

    • Supplementary Materials and Methods, Figure Legends
    • Supplementary Figure 1 - Claudin-4 expression in patient tumors.
    • Supplementary Figure 2 - Apoptotic response of cells with high and low claudin-4 expression.
    • Supplementary Figure 3 - Annexin V binding in response to CMP and paclitaxel.
    • Supplementary Figure 4 - Apoptotic response of cells with claudin-4 expression knocked down.
    • Supplementary Figure 5 - Images of apoptotic response (loss of claudin-4 expression).
    • Supplementary Figure 6 - Images of apoptotic response (claudin-4 overexpression).
    • Supplementary Figure 7 - Apoptotic response to paclitaxel with claudin-4 overexpression.
PreviousNext
Back to top
Molecular Cancer Research: 17 (3)
March 2019
Volume 17, Issue 3
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Ovarian Tumor Cell Expression of Claudin-4 Reduces Apoptotic Response to Paclitaxel
(Your Name) has forwarded a page to you from Molecular Cancer Research
(Your Name) thought you would be interested in this article in Molecular Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Ovarian Tumor Cell Expression of Claudin-4 Reduces Apoptotic Response to Paclitaxel
Christopher Breed, Douglas A. Hicks, Patricia G. Webb, Carly E. Galimanis, Benjamin G. Bitler, Kian Behbakht and Heidi K. Baumgartner
Mol Cancer Res March 1 2019 (17) (3) 741-750; DOI: 10.1158/1541-7786.MCR-18-0451

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Ovarian Tumor Cell Expression of Claudin-4 Reduces Apoptotic Response to Paclitaxel
Christopher Breed, Douglas A. Hicks, Patricia G. Webb, Carly E. Galimanis, Benjamin G. Bitler, Kian Behbakht and Heidi K. Baumgartner
Mol Cancer Res March 1 2019 (17) (3) 741-750; DOI: 10.1158/1541-7786.MCR-18-0451
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Heme-Sensing Pathway Dictates Apoptotic Response
  • ERα66/ERα36 Ratio Regulates 24R,25(OH)2D3 Response
  • SOX9 Regulates TNBC Survival and Metastasis
Show more Cell Fate Decisions
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Rapid Impact Archive
  • Meeting Abstracts

Information for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCR

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Research
eISSN: 1557-3125
ISSN: 1541-7786

Advertisement